Snapshots from the Edge: Why Oncologists Are Leading the AI-Driven Shift to Personalized Medicine

“I was involved in introducing biosimilar oncology medicines: the challenge was huge, because oncologists really want to know that things work. But they’re going to be very receptive to new ways of working, and how they can bring value to their patients.”

John Harris, GT LifeScience CTO, outlines why oncologists will tend to be the most receptive clinicians to the changes in workflow and practice required by AI-DDS, also leading the way towards personalised medicine.